Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Grimwade

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Hematology. American Society of Hematology. Education Program|December 17, 2009
Independent prognostic factors for AML outcomeDavid Grimwade, Robert K Hills
Leukemia Research|August 3, 2010
Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?David Grimwade, Martin S Tallman
Oncology (Williston Park, N.Y.)|August 15, 2012
Getting to the heart of improving outcomes for patients with acute promyelocytic leukemiaDavid Grimwade, Alan K Burnett
Blood|July 23, 2014
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|February 20, 2015
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Lancet (London, England)|July 20, 2002
Minimal residual disease evaluation in acute myeloid leukaemiaJohn A Liu Yin, David Grimwade
British Journal of Haematology|July 20, 2006
Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is nowNick Goulden, Paul Virgo, David Grimwade
Acta Haematologica|June 5, 2004
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemiaAndreas Reiter, Eva Lengfelder, David Grimwade
Current Opinion in Oncology|September 1, 2010
Assessment of minimal residual disease in acute myeloid leukemiaDavid Grimwade, Paresh Vyas, Sylvie Freeman
The New England Journal of Medicine|August 11, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLRobert K Hills, Adam Ivey, David Grimwade, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Hematology. American Society of Hematology. Education Program|December 17, 2009
Independent prognostic factors for AML outcomeDavid Grimwade, Robert K Hills
Leukemia Research|August 3, 2010
Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?David Grimwade, Martin S Tallman
Oncology (Williston Park, N.Y.)|August 15, 2012
Getting to the heart of improving outcomes for patients with acute promyelocytic leukemiaDavid Grimwade, Alan K Burnett
Blood|July 23, 2014
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|February 20, 2015
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Lancet (London, England)|July 20, 2002
Minimal residual disease evaluation in acute myeloid leukaemiaJohn A Liu Yin, David Grimwade
British Journal of Haematology|July 20, 2006
Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is nowNick Goulden, Paul Virgo, David Grimwade
Acta Haematologica|June 5, 2004
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemiaAndreas Reiter, Eva Lengfelder, David Grimwade
Current Opinion in Oncology|September 1, 2010
Assessment of minimal residual disease in acute myeloid leukemiaDavid Grimwade, Paresh Vyas, Sylvie Freeman
The New England Journal of Medicine|August 11, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLRobert K Hills, Adam Ivey, David Grimwade, et al.
Pageof 11